NASDAQ$AMGN
Amgen Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Amgen's financial performance in Q2 2021 reflected a recovery from pandemic effects, marked by volume-driven growth and strategic pipeline advancements.
Amgen reported a 5% increase in total revenues to $6.5 billion for Q2 2021, driven by higher unit demand. GAAP EPS decreased 73% to $0.81, influenced by a $1.5 billion write-off related to acquired IPR&D. Non-GAAP EPS increased 4% to $4.38, bolstered by revenue growth and fewer shares outstanding. The company reaffirmed its full-year revenue guidance and revised GAAP EPS guidance.
- Total revenues increased by 5% to $6.5 billion, driven by higher unit demand.
- GAAP EPS decreased 73% to $0.81 due to a write-off of acquired IPR&D.
- Non-GAAP EPS increased 4% to $4.38, supported by revenue growth and fewer shares outstanding.
- Free cash flow was $1.7 billion, impacted by the timing of tax payments.
Headline financials
Revenue & EPS history
Amgen · Revenue · Quarterly
$6.53B
Revenue by segment
Amgen · $5.67B total across 16 segments · Q2 2021
- Enbrel$1.14B-8.2%20.2%
- Prolia$814M+23.5%14.4%
- Otezla$534M-4.8%9.4%
- XGEVA$488M+12.2%8.6%
- Neulasta$486M-18.0%8.6%
- Aranesp$367M-5.2%6.5%
- MVASI$294M+70.9%5.2%
- Repatha$286M+43.0%5.0%
- KYPROLIS$280M+10.7%4.9%
- Nplate$245M+26.9%4.3%
- Vectibix$239M+22.6%4.2%
- EVENITY$131M+29.7%2.3%
- BLINCYTO$108M+16.1%1.9%
- AMJEVITA/AMGEVITA$107M+72.6%1.9%
- Other products$77M+28.3%1.4%
- Parsabiv$71M-61.8%1.3%
Forward guidance
Amgen reaffirmed its total revenue guidance for 2021 to be in the range of $25.8 billion to $26.6 billion. The company revised its GAAP EPS guidance to $8.84-$9.90 and reaffirmed its non-GAAP EPS guidance to $16.00-$17.00.
Tailwinds
- Total revenues are expected to be in the range of $25.8 billion to $26.6 billion.
- Non-GAAP EPS is projected to be between $16.00 and $17.00.
- Capital expenditures are estimated to be approximately $900 million.
- Share repurchases are expected to be at the upper end of the $3.0 billion to $5.0 billion range.
- Tax rate on a non-GAAP basis is expected to be in the range of 13.5% to 14.5%.
Headwinds
- GAAP EPS is projected to be between $8.84 and $9.90.
- Tax rate on a GAAP basis is expected to be in the range of 13.0% to 14.5%.
- The cumulative decrease in diagnoses over the course of the pandemic has suppressed the volume of new patients starting treatment, which we expect to continue to impact our business during the second half of the year.
- Expect further reduction in the net selling price on a sequential basis as the number of Medicare Part D patients receiving Repatha increases.
- Going forward, we expect net selling price for Enbrel to continue to decline year-over-year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.3%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+0.1%
Avg return
30 days after
53%
39 / 73 earnings
Positive
+12.2%
Q1 2024
Best reaction
-8.7%
Q3 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.9% | -4.4% | -2.7% | |
| Q4 2025 | +3.0% | +11.0% | +9.1% | |
| Q3 2025 | +7.7% | +9.1% | +11.2% | |
| Q2 2025 | -5.1% | -5.0% | -5.5% | |
| Q1 2025 | -1.1% | -2.8% | +1.6% | |
| Q4 2024 | +6.5% | +2.0% | +12.4% | |
| Q3 2024 | +1.3% | +0.3% | -10.5% | |
| Q2 2024 | -3.9% | -0.8% | -0.3% | |
| Q1 2024 | +12.2% | +8.3% | +10.3% | |
| Q4 2023 | -8.1% | -9.6% | -15.3% | |
| Q3 2023 | -0.9% | +2.5% | +2.5% | |
| Q2 2023 | +5.6% | +13.2% | +11.4% | |
| Q1 2023 | +0.4% | -1.2% | -9.2% | |
| Q4 2022 | -2.1% | -2.6% | -6.7% | |
| Q3 2022 | +0.0% | +8.7% | +6.1% | |
| Q2 2022 | -0.4% | +0.5% | -1.9% | |
| Q1 2022 | -4.7% | -7.6% | +2.2% | |
| Q4 2021 | +8.5% | +2.7% | +4.2% | |
| Q3 2021 | +4.0% | +1.9% | -4.1% | |
| Q2 2021 | -4.8% | -4.0% | -5.8% | |
| Q1 2021 | -7.4% | -6.2% | -7.9% | |
| Q4 2020 | -1.4% | -1.7% | -7.7% | |
| Q3 2020 | -2.5% | -1.5% | +0.6% | |
| Q2 2020 | -1.9% | -3.5% | -0.3% | |
| Q1 2020 | -2.0% | +0.3% | -2.5% | |
| Q4 2019 | -4.9% | -2.4% | -12.1% | |
| Q3 2019 | +2.9% | +6.3% | +14.4% | |
| Q2 2019 | +6.0% | +6.3% | +17.5% | |
| Q1 2019 | -2.8% | -2.1% | -6.7% | |
| Q4 2018 | -3.7% | -2.5% | -1.0% | |
| Q3 2018 | +2.4% | -0.6% | +7.5% | |
| Q2 2018 | -0.3% | +1.8% | +1.9% | |
| Q1 2018 | +0.1% | +1.6% | +1.9% | |
| Q4 2017 | +0.5% | -5.1% | -0.5% | |
| Q3 2017 | -2.1% | -3.2% | -5.7% | |
| Q2 2017 | -2.9% | -3.6% | -6.1% | |
| Q1 2017 | -1.2% | -1.3% | -5.9% | |
| Q4 2016 | +4.9% | +4.5% | +12.9% | |
| Q3 2016 | -8.7% | -11.5% | -8.5% | |
| Q2 2016 | +2.2% | +3.9% | +2.6% | |
| Q1 2016 | -1.7% | — | — | |
| Q4 2015 | +1.5% | — | — | |
| Q3 2015 | -0.9% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | +1.9% | — | — | |
| Q4 2014 | -3.2% | — | — | |
| Q3 2014 | +6.7% | — | — | |
| Q2 2014 | +6.0% | — | — | |
| Q1 2014 | -3.2% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | +1.8% | — | — | |
| Q2 2013 | -1.0% | — | — | |
| Q1 2013 | -7.5% | — | — | |
| Q4 2012 | -0.8% | — | — | |
| Q3 2012 | +0.8% | — | — | |
| Q2 2012 | +7.6% | — | — | |
| Q1 2012 | +0.2% | — | — | |
| Q4 2011 | -0.8% | — | — | |
| Q3 2011 | +4.9% | — | — | |
| Q2 2011 | -3.0% | — | — | |
| Q1 2011 | -1.5% | — | — | |
| Q4 2007 | +0.7% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2008 | +0.7% | — | — | |
| Q3 2010 | -0.9% | — | — | |
| Q2 2010 | -0.4% | — | — | |
| Q1 2009 | +1.5% | — | — | |
| Q1 2010 | +1.2% | — | — | |
| Q4 2009 | +0.5% | — | — | |
| Q3 2009 | +1.6% | — | — | |
| Q4 2008 | +3.8% | — | — | |
| Q2 2009 | +3.8% | — | — | |
| Q2 2008 | +3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro